Diabetics who rely on glucose monitors are alarmed by recall linked to 7 deaths

Diabetes Tech Recall Sparks Concern After 7 Fatal Incidents

Michael Ford, a 68-year-old man with Type 2 diabetes, was managing his condition with regular care. His son, Davonte Ford, provided daily assistance, including bathing, medication, and responding to fluctuations in his blood sugar levels. One November morning, the pair awoke to a low glucose alert from Michael’s FreeStyle Libre 3 Plus sensor, part of Abbott’s advanced glucose monitoring system. Davonte acted on the reading, giving his father fast-acting carbohydrates as instructed by medical professionals.

Eight days later, Abbott issued a critical warning about potential false low readings from 3 million FreeStyle Libre 3 and Libre 3 Plus sensors. The company cited seven deaths and over 730 severe injuries globally. Davonte, 25, later filed a lawsuit, alleging the sensor’s displayed number was “catastrophically inaccurate.” Despite the alert, Michael’s blood sugar remained low, leading Davonte to administer additional carbs. However, the readings persisted, eventually revealing a critical error when paramedics found his actual level at 551 mg/dL—a level more than three times the normal range.

“My heart just dropped. Obviously, there’s a problem here,” Davonte said, describing the moment he realized the monitor had misread his father’s condition. The lawsuit claims Michael’s death in the hospital ICU followed multiple cardiac arrests, all triggered by the faulty device.

Diabetes, a condition where the body either lacks insulin or struggles to use it, demands constant monitoring. With 40.1 million Americans affected, uncontrolled glucose levels can lead to severe complications, including vision loss and organ damage. The Abbott recall has intensified fears about the reliance on technology for managing diabetes, highlighting risks when devices fail.

At least three class-action lawsuits have been proposed in the U.S., alongside Davonte’s wrongful death claim. Others in California, Washington, and North Carolina plan to seek compensation for injuries caused by incorrect readings. Legal experts question whether Abbott’s reported 860 injuries fully capture the issue, noting Michael’s death was excluded because his sensor’s serial number wasn’t listed in the recall.

Abbott spokesperson Lindsy Delco expressed sorrow over Michael’s passing, stating the company thoroughly investigates adverse events. She clarified that not all sensors in affected batches had the same issue and that the problem stemmed from a production defect, which was swiftly resolved. The company has yet to respond to Davonte’s legal action.

Expert Insight on Glucose Monitoring Technology

Dr. Amy Warriner, an endocrinologist at the University of Alabama at Birmingham, praised continuous glucose monitors as a “complete game changer” for patients. These devices replaced traditional finger sticks, which require frequent blood tests, by measuring glucose levels in subcutaneous fluid. However, the recall underscores the vulnerability of patients when such technology malfunctions, raising concerns about both physical and mental well-being in the face of unreliable data.